Center for the Evaluation of Value and Risk in Health

Center for the Evaluation of Value and Risk in Health The Center for the Evaluation of Value and Risk in Health (CEVR) analyzes the benefits, risks and co Founded in January 2006 by Peter Neumann, Sc.D.

and Joshua Cohen, Ph.D., the Center for the Evaluation of Value and Risk in Health (CEVR) analyzes the benefits, risks and costs of strategies to improve health and health care. CEVR undertakes projects to determine the cost-effectiveness of health care interventions, advances methods development, and helps train the next generation of practitioners. We also seek to inform national clinical and public health policy issues. Finally, CEVR has developed and maintains two internationally-known databases that are indispensable resources for health care stakeholders: the Cost-effectiveness Analysis Registry and the National Coverage Determinations Database. CEVR conducts customized analyses for government agencies, private foundations and industry groups. In all our work, we maintain our research independence and freedom to publish.

Published by our own James Chambers in the The American Journal of Managed Care: http://www.ajmc.com/journals/issue/2016...
10/19/2016

Published by our own James Chambers in the The American Journal of Managed Care: http://www.ajmc.com/journals/issue/2016/2016-vol22-n8/the-impact-of-formulary-drug-exclusion-policies-on-patients-and-healthcare-costs

Be sure to check out Dr. Chamber's infor-graphic and podcast discussing the study in detail!

Info-graphic: http://www.ajmc.com/newsroom/infographic-do-formulary-drug-exclusions-save-money-as-promised

Podcast: http://www.ajmc.com/managed-care-cast/drug-formulary-exclusions-dr-patricia-salber-interviews-dr-james-chambers

The authors review empirical evaluations of drug exclusion policies to examine their impact on patients and on healthcare costs.

09/13/2016

New JAMA article out today on updates to 20-year-old guidelines and recommendations for evaluating cost-effectiveness in health and medicine

By browsing our interactive website, you can learn about the latest published cost-effectiveness analyses. The CEA Registry offers detailed information on more than 2500 cost-effectiveness analyses covering a wide array of diseases and intervention types. We are happy to report that visits to our we...

01/25/2016

CEA Registry Data updated through 2014

By browsing our interactive website, you can learn about the latest published cost-effectiveness analyses. The CEA Registry offers detailed information on more than 2500 cost-effectiveness analyses covering a wide array of diseases and intervention types. We are happy to report that visits to our we…

Reminder: register now for the International Pharmacoeconomic Conference on Alzheimer’s Disease (IPECAD) in Boston on No...
10/02/2015

Reminder: register now for the International Pharmacoeconomic Conference on Alzheimer’s Disease (IPECAD) in Boston on November 19-20.

The IPECAD conferences are unique. They exclusively addressing issues related to economic evaluation of diagnostics and treatments for Alzheimer disease, bringing together leading experts and opinion leaders from the academia, regulatory bodies and the pharmaceutical industry.

For more information and to register, please go to https://research.tufts-nemc.org/cear4/AboutUs/CEVREvents.aspx

Page of upcoming and previous events CEVR has conducted.

09/30/2015

The Case for Value: Dr. Peter Neumann and other experts will speak on Monday, October 5 at MassBio in Cambridge, MA. For more information and to register: http://ow.ly/Szz8q

“Value" is becoming is increasingly critical for innovators to deliver to both patients and the healthcare system overall - without value there may be approval but neither reimbursement by payers, adoption by providers nor acceptance by patients.

09/25/2015

A new worked example (Palliative Care) and Chapter 8 from the Second Panel on Cost-Effectiveness in Health and Medicine are available for review and comments through October 16th.

http://healtheconomics.tuftsmedicalcenter.org/ctcia/booklink.aspx

The 2nd Panel on Cost Effectiveness in Health and Medicine was convened in 2012 to update the original Panel book. As we prepare for launch of the new book in 2016, we are seeking public review and comments on our draft chapters. We are posting draft chapters as they become available, during Septemb…

09/25/2015

New paper: Private Payers Disagree with Medicare Over Medical Device Coverage About Half The Time Health Affairs http://tinyurl.com/p5cchcm

By browsing our interactive website, you can learn about the latest published cost-effectiveness analyses. The CEA Registry offers detailed information on more than 2500 cost-effectiveness analyses covering a wide array of diseases and intervention types. We are happy to report that visits to our we…

Big Price Increase for Tuberculosis Drug Is Rescinded http://nyti.ms/1OM1WGh
09/22/2015

Big Price Increase for Tuberculosis Drug Is Rescinded http://nyti.ms/1OM1WGh

Rodelis, which acquired cycloserine and promptly raised its price more than twentyfold, returned it to the foundation that had previously owned the drug.

09/17/2015

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials:

https://research.tufts-nemc.org/cear4/Resources/CEARegistryBlog/tabid/69/EntryId/437/Recently-published-studies-9-17-2015.aspx

By browsing our interactive website, you can learn about the latest published cost-effectiveness analyses. The CEA Registry offers detailed information on more than 2500 cost-effectiveness analyses covering a wide array of diseases and intervention types. We are happy to report that visits to our we…

This systematic review from Annals of Internal Medicine examines the economic impact of programs intended to prevent typ...
09/16/2015

This systematic review from Annals of Internal Medicine examines the economic impact of programs intended to prevent type 2 diabetes by promoting diet and physical activity.

From Centers for Disease Control and Prevention, Atlanta, Georgia, and HealthPartners Research Foundation, Minneapolis, Minnesota.

09/10/2015

New study on cost-effectiveness of herpes zoster vaccine:

Editor's Note: This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Address

Boston, MA
02111

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Center for the Evaluation of Value and Risk in Health posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category